hotspot -WSS

hotspot

author：hotspot 2025-09-27 18:22:34 - browse：42569

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Getting Alzheimer's drug Leqembi to patients can be a challenge

focus

WSS

Cell therapy fails to slow type 1 diabetes, but safety is established

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Key Senate committee drafts bipartisan bill to stem drug shortages

Stroke rates rising, especially in working

Dogs on Prozac: What pet anti

Congress: Prevent baby formula shortages by passing a new bill

explore

hotspot

leisure time

New air purifier tech could be key to improving indoor air quality

Stroke rates rising, especially in working

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

More tobacco lobbyists active in statehouses

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

MultiPlan and major insurers sued for alleged medical price

Affirmative action in medical school literally saved lives

Hospitals need to get ahead of regulations on climate change

Sports medicine is finally prioritizing gender equality

Decentralized clinical trials need collaboration to achieve wider use

leisure time

Unmasking the 'centricity' illusion in clinical trials

J&J reports mixed data on next

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Getting Alzheimer's drug Leqembi to patients can be a challenge

Element Biosciences CEO lays out genome sequencing strategy

Getting Alzheimer's drug Leqembi to patients can be a challenge

hotspot

hotspot

focus

hotspot